Patents by Inventor Peter G. Traber

Peter G. Traber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THE USE THEREOF
    Publication number: 20230132265
    Abstract: Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.
    Type: Application
    Filed: June 8, 2022
    Publication date: April 27, 2023
    Inventors: Eliezer Zomer, Peter G. Traber, Raphael Nir, Sharon Shechter, Joseph M. Johnson, Ryan George
  • SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THE USE THEREOF
    Publication number: 20230127345
    Abstract: Aspects of the invention relate to novel synthetic compounds having a binding affinity with galectin proteins.
    Type: Application
    Filed: November 4, 2022
    Publication date: April 27, 2023
    Inventors: Sharon Shechter, Eliezer Zomer, Peter G. Traber, Raphael Nir, Joseph M. Johnson, Ryan George
  • Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof
    Publication number: 20230116370
    Abstract: Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins.
    Type: Application
    Filed: July 8, 2022
    Publication date: April 13, 2023
    Inventors: Raphael NIR, Eliezer ZOMER, Peter G. TRABER, Joseph M. JOHNSON, Ryan GEORGE, Sharon SHECHTER
  • Compounds for the prevention and treatment of medical disorders and uses thereof
    Patent number: 11583530
    Abstract: Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: February 21, 2023
    Assignee: GALECTIN SCIENCES, LLC
    Inventors: Raphael Nir, Eliezer Zomer, Peter G. Traber, Joseph M. Johnson, Ryan George, Sharon Shechter
  • Compounds for the prevention and treatment of diseases and the use thereof
    Patent number: 11576924
    Abstract: Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 14, 2023
    Assignee: GALECTIN SCIENCES, LLC
    Inventors: Eliezer Zomer, Peter G. Traber, Raphael Nir, Sharon Shechter, Joseph M. Johnson, Ryan George
  • COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASES
    Publication number: 20230000898
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Application
    Filed: June 29, 2022
    Publication date: January 5, 2023
    Inventors: Eliezer ZOMER, Peter G. TRABER, Anatole A. KLYOSOV, Elena CHEKHOVA
  • Methods for treatment of arthritis
    Patent number: 11413303
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: August 16, 2022
    Assignee: GALECTIN THERAPEUTICS, INC.
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Composition of Novel Carbohydrate Drug for Treatment of Human Diseases
    Publication number: 20210093656
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Application
    Filed: September 28, 2020
    Publication date: April 1, 2021
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Composition of novel carbohydrate drug for treatment of human diseases
    Patent number: 10799525
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 13, 2020
    Assignee: Galectin Therapeutics, Inc.
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Compounds for the Prevention and Treatment of Diseases and the Use Thereof
    Publication number: 20200155586
    Abstract: Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 21, 2020
    Inventors: Eliezer Zomer, Peter G. Traber, Raphael Nir, Sharon Shechter, Joseph M. Johnson, Ryan George
  • Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof
    Publication number: 20200147088
    Abstract: Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins.
    Type: Application
    Filed: August 3, 2018
    Publication date: May 14, 2020
    Inventors: Raphael Nir, Eliezer Zomer, Peter G. Traber, Joseph M. Johnson, Ryan George, Sharon Shechter
  • Composition of Novel Carbohydrate Drug for Treatment of Human Diseases
    Publication number: 20200078390
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Application
    Filed: July 30, 2019
    Publication date: March 12, 2020
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof
    Publication number: 20200061095
    Abstract: Aspects of the invention relate to novel synthetic compounds for treatment of metabolic diseases partially associated with systemic insulin resistance caused by Galectin proteins binding and inhibiting insulin and TGFb1 receptors causing physiological disturbances in the insulin pathways.
    Type: Application
    Filed: May 11, 2018
    Publication date: February 27, 2020
    Inventors: Peter G. Traber, Eliezer Zomer, Deirdre Slate, Joseph M. Johnson, Ryan George, Sharon Shechter, Raphael Nir
  • SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THE USE THEREOF
    Publication number: 20190367552
    Abstract: Aspects of the invention relate to novel synthetic compounds having a binding affinity with galectin proteins.
    Type: Application
    Filed: March 3, 2017
    Publication date: December 5, 2019
    Inventors: Sharon Shechter, Eliezer Zomer, Peter G. Traber, Raphael Nir, Joseph M. Johnson, Ryan George
  • Composition of novel carbohydrate drug for treatment of human diseases
    Patent number: 10420793
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 24, 2019
    Assignee: Galectin Therapeutics, Inc.
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Method for enhancing specific immunotherapies in cancer treatment
    Patent number: 10398778
    Abstract: Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: September 3, 2019
    Assignees: Galectin Therapeutics, Inc., Providence Health & Services—Oregon
    Inventors: Peter G. Traber, William L. Redmond, Eliezer Zomer, Anatole Klyosov, Stefanie N. Linch
  • Composition of Novel Carbohydrate Drug for Treatment of Human Diseases
    Publication number: 20180256626
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Method for Enhancing Specific Immunotherapies in Cancer Treatment
    Publication number: 20180236084
    Abstract: Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
    Type: Application
    Filed: January 22, 2018
    Publication date: August 23, 2018
    Inventors: Peter G. Traber, William L. Redmond, Eliezer Zomer, Anatole Klyosov, Stefanie N. Linch
  • Composition of novel carbohydrate drug for treatment of human diseases
    Patent number: 9974802
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-?-L-arabinose (Ara) residues.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: May 22, 2018
    Assignee: Galectin Therapeutics, Inc.
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Method for treatment of pulmonary fibrosis
    Patent number: 9968631
    Abstract: Methods and compositions of the invention relate to the treatment of pulmonary fibrosis.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: May 15, 2018
    Assignee: Galectin Therapeutics, Inc.
    Inventor: Peter G. Traber